Purpose: In patients with Alzheimer's disease (AD), the loss of cerebral nicotinic acetylcholine receptors (nAChRs) that are implicated in higher brain functions has been reported. However, it is unclear if nAChR deficits occur in association with cognitive impairments. The purpose of this study was to assess the relationship between nAChR deficits and cognitive impairments in a mouse model of AD (APP/PS2 mice). Procedures: The cognitive abilities of APP/PS2 and wild-type mice (aged 2-16 months) were evaluated using the novel object recognition test. tomography (SPECT) imaging was also performed in both mice at 12 months of age. Furthermore, each age cohort was investigated for changes in cognitive ability and expression levels of α7 nAChRs and N-methyl-D-aspartate receptors (NMDARs).
Introduction
Alzheimer's disease (AD), the most common chronic neurodegenerative disorder, is characterized by progressive cognitive impairments associated with a massive loss of synapses and neurons in the brain. At present, assessing its progression and severity requires several medical evaluations, such as mental state testing [1] . However, the results of these clinical diagnoses are frequently obscure because the current diagnosis of AD relies largely on the documentation of mental decline [2] , and there is currently no definitive diagnostic test for assessing the cerebral functional changes that are fundamental to AD pathology. Thus, establishing a biomarker that reflects cognitive function is expected to aid in the understanding of the progression of AD and be beneficial clinically.
Nuclear medical imaging technology is a promising tool for in vivo monitoring of molecular processes using positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Since this technique is non-invasive and highly quantitative, functional neuroimaging is being investigated as a possible method of identifying biomarkers for AD. Although much effort has been made to develop imaging probes for amyloid-β (Aβ), one of the hallmark proteins in AD, Aβ-PET imaging in patients with AD showed that the accumulation of Aβ in the brain did not necessarily reflect the cognitive decline seen in these patients [3] . Furthermore, cerebral 2-deoxy-2-[
18 F]fluoro-Dglucose ([ 18 F]FDG)-PET is used clinically as an index of central nervous system (CNS) activity. Although [ 18 F]FDG-PET has been found to be better than other imaging modalities for AD diagnosis, it is difficult to use to characterize abnormal activity in late-onset patients with AD [4] .
Nicotinic acetylcholine receptors (nAChRs) in the CNS are reported to play an important role in higher brain functions, including learning, memory, and recognition [5] . Neuronal α4β2 and α7 nAChRs are the two most predominant subtypes expressed in the CNS [6] . Thus, these subtypes are thought to be involved in the majority of nAChR signaling, and their dysfunction is believed to be related to several CNS disorders, including AD. Moreover, several acetylcholinesterase inhibitors, which target nAChRs directly or indirectly, have been developed for the treatment of AD and have been used successfully in the prevention of AD disease progression [7] . These inhibitors are reported to upregulate α4β2 nAChRs and to protect neuronal cells against glutamate neurotoxicity, which has been implicated in AD [8] . Specifically, it has been reported that stimulation of α4β2 nAChRs inhibits Aβ cytotoxicity [9] . Thus, α4β2 nAChRs are one of the potential therapeutic targets to prevent the pathological progress of AD. Several imaging probes have been developed to visualize α4β2 nAChRs using PET/SPECT, including 5 [11, 12] ; however, there are some that have not [13] . A potential explanation for these heterogenous results is that clinical trials are directly affected by factors such as secondhand smoke and the varying combinations of symptoms. As a complement to clinical studies, many types of transgenic mice have recently been developed with expressions of specific altered genes that relate to human diseases. Thus, studies using transgenic mice as animal models of AD would be more useful than clinical trials to elucidate directly whether the nAChR deficits occur in association with cognitive impairments or not.
In this study, we aimed to investigate the age-related changes in cognitive function, cerebral glucose metabolism, and nAChR expression in the brain as the disease advances using an AD mouse model (APP/PS2 mouse).
Our [
125 I]5IA-autoradiography (ARG) analysis showed that α4β2 nAChR deficits in the brains of APP/PS2 mice occurred when cognitive impairment was first observed. It was supported by a reduction in α4 nAChR protein levels, as detected by Western blotting. The [
123 I]5IA-SPECT analysis was sufficiently sensitive to assess the decline in α4β2 nAChRs in the brains of APP/PS2 mice at 12 months of age. Conversely, changes in glucose uptake and α7 nAChR expression were not associated with cognitive impairments in the AD model. This suggests that decreased α4β2 nAChR density in the brain acts an imaging biomarker that reflects the state of cognitive function in AD.
Materials and Methods

Animals
Animal experiments were performed in accordance with the guidelines of the Okayama University and Kyoto University Animal Care Committees. The experimental procedures performed were approved by both care committees. All studies were conducted with Tg2576 × PS2 (APP/PS2) double-transgenic mice [14] 
Novel Object Recognition Test
The novel object recognition (NOR) test was performed on all APP/PS2 and wild-type mice used at 2, 6, 12, and 16 months of age (n = 9-21 per group) using a modification of the procedure by Oulès et al. [16] . This test was conducted in an open field (44 × 44 cm). Initially, the animals were habituated to the environment for 10 min/day for 3 days. On day 4, two identical objects (50-mL conical polypropylene tubes) were placed in the field, and animals were allowed to explore the objects for 10 min. On day 5, the animals were returned to the area with one familiar object (50-mL conical polypropylene tube) and one novel object (brown glass bottle) and allowed to explore the objects for 5 min. The time spent exploring each object was recorded and analyzed using ANY-maze software (Stoelting Co., IL, USA). An exploration preference (EP) index was calculated as follows: EP values (%) = time spent exploring the novel object / (time spent exploring the novel object + time spent exploring the familiar object) × 100. Animals that spent G 8 s exploring the objects during the 10-min training session were omitted from the analysis (1-9 mice per group).
Ex Vivo Dual Autoradiography with [ . Autoradiographic images were gained and analyzed as reported previously [10] . Two independent measurements were taken from the thalamus, cerebellum, striatum, cerebral cortex, and hippocampus identified using a mouse brain atlas. The accumulation of radioactivity within regions of interest (ROIs) was calculated according to the following equation corrected for injection dose (MBq) and body weight (g): radioactivity accumulation (%ID*BW) = (radioactivity for each ROI) / (injected radioactivity / animal body weight) × 100.
Histological Staining of Amyloid-β
Upon completion of the ex vivo dual ARG study, serial sections were stained with thioflavin-S using the same procedure as that stated by Iikuni et al. [17] . The digital images (n = 4 per group) taken under the same conditions were analyzed with BZ-X analyzer ver. 1.3.1.1 software (Keyence Corp., Osaka, Japan). The areas of interest of the hippocampus and cortex were manually outlined in each image, and the areas stained by thioflavin-S were quantified.
SPECT/CT Imaging
After injection of [ 123 I]5IA (4.6-7.6 MBq) into each APP/ PS2 and wild-type mouse (n = 4-5) via the tail vein, dynamic SPECT/CT imaging was conducted using the same methods as those in our previous report [15] . For an accurate ROI definition, each mouse was subjected to magnetic resonance (MR) brain imaging 1 day prior to SPECT/CT imaging. Two spheroidal ROIs in the frontal cortex, striatum, hippocampus, thalamus, and cerebellum were positioned on MR images and then applied to SPECT images, as previously reported [15] . Standardized uptake values (SUVs) were calculated according to the following equation: SUV = radioactivity for each ROI (kBq/cc) / (injected dose [kBq] / body weight [g]) × 100.
Immunoblotting
The hippocampi of APP/PS2 and wild-type mice at 2, 12, and 16 months of age (n = 4 per group) were homogenized in a radioimmunoprecipitation assay buffer containing protease inhibitor. The electrophoresis and immunoblotting were performed via the same procedure as that stated by Oulès et al. [16] . The antibody resources and the details for application are shown in Supplemental Table 1 (see  electronic supplementary 
material (ESM)).
Statistical Analysis
GraphPad Prism ver. 7 (GraphPad, San Diego, CA, USA) was used for all statistical analyses. The comparisons between two groups were performed with Student's t test. The statistical data among three or more groups were assessed by analysis of variance (ANOVA) with Bonferroni's post hoc test. Correlation coefficients were assessed using Pearson's analysis. Differences with a P value G 0.05 were considered to be statistically significant. All data are expressed as mean ± standard deviation (SD). Figure 1 shows the time-dependent changes in Aβ deposition in the brains of APP/PS2 mice. The presence of Aβ plaques was first observed at 6 months of age. After 12 months of age, the amyloid-β plaque loads in the hippocampus and cortex were significantly increased compared to 2 and 6 months of age (*P G 0.05, **P G 0.01, ***P G 0.001, ****P G 0.0001 between indicated groups, n = 4 mice per group). Conversely, no plaque was found in the wild-type mice at any age (data not shown). Figure 2 shows the time-dependent changes in cognitive abilities (expressed as EP values) of APP/PS2 and wild-type mice. No significant difference was found between the APP/ PS2 and wild-type mice at 2-6 months of age in terms of novel object recognition memory. However, APP/PS2 mice at 12 months of age showed a clear reduction in EP values as compared with those of wild-type mice (P G 0.0001), and APP/PS2 mice at 16 months of age showed the same level of cognitive deficit as at 12 months of age (P G 0.01). Conversely, no significant differences were found in EP values in wild-type mice at any age. Figure 3 shows the age-related changes in [ 18 F]FDG uptake in each brain region of the APP/PS2 and wild-type mice. No significant differences were observed in any of the brain regions of the APP/PS2 mice at 2 months of age as compared with in wild-type mice. At 6 months of age, glucose uptake tended to increase in the cortex and hippocampus of APP/PS2 mice as compared with in wildtype mice. This tendency was terminated in all brain regions in APP/PS2 mice at 12 months of age, however, and at 16 months of age, glucose metabolism tended to decrease in the hippocampus and thalamus of APP/PS2 mice as compared with in the wild-type mice. However, these differences mentioned above were not statistically significant in any group. No age-related change in glucose metabolism was detected in the wild-type mice. As compared with wild-type mice, no significant difference was observed in any of the brain regions examined at 2 months of age in APP/PS2 mice. At 6 months, [
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125 I]5IA accumulation tended to increase in the hippocampus of APP/ PS2 mice as compared with in wild-type mice and showed almost the same levels in the other four brain regions as that noted in the wild-type mice. In 12-month-old APP/PS2 mice, however, the [ 125 I]5IA accumulation decreased in the cortex, hippocampus, and thalamus (P G 0.05, n = 4-5 per group) in comparison with the results seen in the wild-type mice. Decreases in [
125 I]5IA accumulation were maintained in all brain regions of the APP/PS2 mice at 16 months of age (striatum: P G 0.05, cortex: P G 0.01, hippocampus and thalamus: P G 0.0005, n = 4-5 per group). In contrast, no significant difference was found in [
125 I]5IA accumulation in the cerebellum in both groups at all the ages examined.
SPECT Imaging with [
123 I]5IA Fig. 5b . The SPECT signals in the frontal cortex and hippocampus (P G 0.01), and thalamus (P G 0.05) of APP/PS2 mice were lower than those detected in wild-type mice (n = 4-5 per group). In contrast, no significant difference was found in SUVs in the cerebellum. These findings were consistent with the results obtained in the ARG study. However, it should be noted that due to the low spatial resolution of SPECT images, radioactivity in the hippocampus, as determined by SPECT imaging, may be overestimated by the influence of high radioactivity in the thalamus.
Expression Levels of nAChRs
To confirm that reduced [ 125 I]5IA accumulation was detected in the brains of APP/PS2 mice at 12 and 16 months of age, we measured the protein levels of α4 and β2 nAChRs. As shown in Fig. 6 , the α4 subunit was reduced at the protein level by 30 % (P G 0.01) in the hippocampus of APP/PS2 mice at 16 months of age as compared with in the wild-type mice at the same age. There were no significant differences in the protein levels of β2 nAChRs between the APP/PS2 and wild-type mice at any age. Additionally, reverse transcription polymerase chain reaction (RT-PCR) analyses revealed no significant change in the mRNA levels of α4 and β2 nAChRs in APP/PS2 mice at 2, 6, 12, or 16 months of age, as compared with wild-type mice of the same ages (Supplemental Figure 1, ESM) .
We also measured the protein levels ( Fig. 6 ) and the mRNA expression levels (Supplemental Figure 1) of α7 nAChR. APP/ PS2 mice showed elevated α7 nAChR protein levels in the hippocampus at 12 and 16 months of age (Fig. 6, P G 0.01) , and Staining for amyloid deposits was detected at 6 months of age. After 12 months of age, the amyloid-β plaque loads in the hippocampus and cortex were significantly increased compared to 2 and 6 months of age (*P G 0.05, **P G 0.01, ***P G 0.001, ****P G 0.0001 between indicated groups). Each column represents an average of four mice, and each bar represents the SD. Scale bars = 1000 μm. mo month. Fig. 2 . Time-dependent changes in learning and memory abilities in APP/PS2 mice. The NOR test was performed in APP/PS2 and wild-type mice at 2, 6, 12, and 16 months of age. APP/PS2 mice showed a lower cognitive ability at 12 months of age (****P G 0.0001 vs. wild-type mice) and at 16 months of age (**P G 0.01 vs. wild-type mice). Each point represents the average ± SD for 5-13 mice. EP explore preference.
also showed elevated α7 nAChR mRNA levels in the hippocampus at 2-16 months of age (2 months: P G 0.05, 6 months: P G 0.01, 12 and 16 months: P G 0.0001, Supplemental Figure 1 ) in comparison with the wild-type mice.
Autoradiographic Analysis of NMDAR Density
The age-related changes in 
Discussion
In this study, we explored the relationship between nAChR deficits, glycometabolism, and cognitive impairments in the presence of amyloid in an APP/PS2 AD mouse model. Dualtracer ARG analysis and SPECT imaging study showed that [ 123/125 I]5IA accumulation decreased in the cortex, hippocampus, and thalamus of 12-month-old APP/PS2 mice as compared with that recorded in the wild-type controls, i.e., at the age when cognitive impairments were first observed. Reductions in the protein levels of α4 nAChRs were also detected in the brains of 16-month-old APP/PS2 mice using Western blotting. However, changes in glucose uptake and α7 nAChR expression were not associated with cognitive impairment.
In the present study, we focused on nAChRs as targets for imaging biomarkers that might be used to identify the cognitive impairments induced by amyloid pathology, because nAChRs are reported to play an important role in cognitive function [5] . In addition, NMDARs are also reported to be involved in the cognitive impairments seen in AD and are one of the targets for AD treatment [18] . Therefore, we evaluated the density of NMDARs in APP/ PS2 mice using an in vitro ARG analysis of [ 3 H]MK-801. ]5IA accumulation in the cortex, hippocampus, and thalamus at 12 months of age (*P G 0.05 vs. wildtype) and in all brain regions at 16 months of age (*P G 0.05 in the striatum, **P G 0.01 in the cortex, and ***P G 0.0005 in the hippocampus and thalamus vs. wild-type). Each point represents the average ± SD for 4-5 mice.
However, no significant difference in [ 3 H]MK-801 binding was observed between the APP/PS2 and wild-type mice (Supplemental Figure 2, ESM) . These results suggest that rather than the density of NMDAR, the density of α4β2 nAChR might be a more sensitive biomarker for the cognitive impairments induced by amyloid pathology.
The NOR test is a validated method for evaluating object cognition and recognition memory [16] . In the present study, APP/PS2 mice exhibited clear cognitive deficits at 12 and 16 months of age, when compared with wild-type mice. Using the Morris water maze test, Toda et al. reported that APP/PS2 mice exhibited impaired spatial learning and memory abilities at 4-5 months of age [14] . Impairment of spatial learning seems to occurr earlier than that of object recognition. This discrepancy is consistent with a previous report that cognitive impairment occurs in APP/PS1 and Tg2576 mice 1-13 months later when assessed by the NOR task rather than by the Morris water maze task [19] . Not all tasks have yielded similar findings, which may be a result of each task assessing different cognitive domains or behavioral aspects. It is possible that brain regions showing a decreased expression of α4β2 nAChRs in the present study are involved in object cognition and recognition memory, not spatial learning.
Our [ 18 F]FDG-ARG analysis showed that glucose uptake increased in the cortex and hippocampus of APP/PS2 mice at 6 months of age as compared with wild-type mice. A previous [
18 F]FDG-PET study also reported significant cerebral hypermetabolism in APP/PS1 mice at 6 months of age [20] . Conversely, the increased glucose uptake that has been shown in several AD mouse models is clearly different from the decreased glucose uptake observed in human patients with AD. The reason for the discrepancy is unclear, but it is hypothesized that increased Ca 2+ signaling and inflammatory responses by microglia and astrocytes affect glucose uptake [21] . Nine-month-old PS2APP mice are reported to show the first signs of an inflammatory response, as revealed by CD45 immunoreactivity and [ 3 H]PK11195 binding analyses [22] . Thus, [ 18 F]FDG might detect the neuropathological inflammatory response in the CNS. An electron microscopy study previously revealed the presence of extracellular Aβ and found that increased levels of insoluble Aβ were present in 5-month-old APP/PS2 mice [14] . Characterization of the age-related changes in intraneuronal/extraneuronal oligomer deposition would provide further information on the relationship between glycometabolism and amyloid pathology in APP/PS2 mice.
Since nAChRs are reported to be involved in higher brain function such as memory and recognition abilities, decreased α4β2 nAChR density could be used as a sensitive biomarker for cognitive impairments related to amyloid pathology. In this study, α4β2 nAChR deficits in the brains of APP/PS2 mice occurred at 12 months of age, which is when the cognitive impairment was first observed. We found deficits in α4β2 nAChR at the protein level, but not at the genetic mRNA level. The discrepancy may be caused by alteration of nAChR synthesis on a different level, such as translation or post-translation modifications, or receptor turnover [23] . Conversely, the mRNA and protein levels of α7 nAChR subunits were significantly higher in the brains of APP/PS2 mice than in wild type mice. Interestingly, a reduction in α7 nAChR levels has been reported in the brains of patients with AD, while an increase in α7 nAChRs was recently detected in PC-12 cells exposed to 5 μM Aβ 1-42 [24] . Since at 6-7 months of age, PS2APP mice showed higher levels of insoluble Aβ in their brains than those observed in AD patients [14] , it could be hypothesized that enhanced expression of α7 nAChR subunits was stimulated directly by higher concentrations of Aβ . Moreover, α7 nAChRs are reported to be essential for inhibiting cytokine synthesis via the cholinergic anti-inflammatory pathway [25] . In the brain of patients with AD, α7 nAChRs may serve an antiinflammatory role affecting neuropathological inflammation. This may be one of the reasons why α7 nAChRs were upregulated in the brain of APP/PS2 mice. The discrepancy between the decline in α4β2 nAChR subunits and increased density of α7 nAChR subunits would be an interesting focal point for AD pathology, and a potential topic for further studies.
Our previous research provided the first evaluation of SPECT imaging of α4β2 nAChRs in the mouse brain [15] . In this study, the [ 123 I]5IA-SPECT analysis was sufficiently sensitive to detect the decline in α4β2 nAChRs in the brains of APP/PS2 mice at 12 months of age. Therefore, measuring α4β2 nAChR density using [
123 I]5IA-SPECT may help in the evaluation of cognitive abilities in AD mouse models, and in the screening of drugs targeting nAChRs.
Conclusions
The deficits of α4β2 nAChR in the brain of an AD mouse model (involving APP/PS2 mice) occurred at 12 months of age, which is when cognitive impairment was first observed. NAChR deficits could be noninvasively detected by [ 123 I]5IA-SPECT in vivo. In contrast, no significant changes in glycometabolism, expression levels of α7 nAChRs, or NMDARs were associated with cognitive impairments in APP/PS2 mice. This result suggests that a reduction in α4β2 nAChR density in the brain could act as an imaging biomarker that reflects cognitive function in AD. . nAChR protein levels in the hippocampus of APP/PS2 mice. The relative quantification of protein levels of a α4, b β2, and c α7 nAChRs in the hippocampus of APP/PS2 mice at 2-16 months of age was measured by Western blotting. Summarized quantitation of Western blot analyses in the hippocampus of APP/PS2 mice are presented to the right. A significant decrease in α4 nAChR levels was observed at 16 months of age (**P G 0.01 vs. wild-type) and a significant increase in α7 nAChRs was observed at 12 and 16 months of age (**P G 0.01 at 12 and 16 months of age vs. wild-type). Values are expressed relative to β-actin, and each point represents the average ± SD for four mice.
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